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Summary
Little is known about the factors that govern the level ofHIV-1 replication in infected individ-
uals . Recent studies (using potent antiviral drugs) of the kinetics of HIV-1 replication in vivo
have demonstrated that steady-state levels of viremia are sustained by continuous rounds of de
novo infection and the associated rapid turnover ofCD4+ T lymphocytes . However, no infor-
mation is available concerning the biologic variables that determine the size of the pool ofT
cells that are susceptible to virus infection or the amount of virus produced from infected cells .
Furthermore, it is not known whether all CD4+ T lymphocytes are equally susceptible to
HIV-1 infection at a given time or whether the infection is focused on cells of a particular state
of activation or antigenic specificity . Although HIV-1 replication in culture is known to be
greatly facilitated by T cell activation, the ability of specific antigenic stimulation to augment
HIV-1 replication in vivo has not been studied . We sought to determine whether vaccination
ofHIV-1-infected adults leads to activation ofvirus replication and the targeting ofvaccine an-
tigen-responsive T cells for virus infection and destruction . Should T cell activation resulting
from exposure to environmental antigens prove to be an important determinant of the steady-
state levels ofHIV-1 replication in vivo and lead to the preferential loss ofspecific populations
ofCD4 + T lymphocytes, it would have significant implications for our understanding of and
therapeutic strategies for HIV-1 disease . To begin to address these issues, HIV-1-infected indi-
viduals and uninfected controls were studied by measurement of immune responses to influ-
enza antigens and quantitation of virion-associated plasma HIV-1 RNA levels at baseline and at
intervals after immunization with the trivalent influenza vaccine . Influenza vaccination resulted
in readily demonstrable but transient increases in plasma HIV-1 RNA levels, indicative of acti-
vation ofviral replication, in HIV-1-infected individuals with preserved ability to immunolog-
ically respond to vaccine antigens . Activation ofHIV-1 replication by vaccination was more
often seen and ofgreater magnitude in individuals who displayed a T cell proliferative response
to vaccine antigens at baseline and in those who mounted a significant serologic response after
vaccination . The fold increase in viremia, as well as the rates ofincrease ofHIV-1 in plasma af-
ter vaccination and rates of viral decline after peak viremia, were higher in individuals with
higher CD4+ T cell counts . These data indicate that important aspects of the host-virus rela-
tionships underlying HIV-1 infection may be gleaned from the careful analysis of interventions
that perturb, either positively or negatively, the steady-state equilibrium of virus replication in
vivo . The potential adverse consequences of vaccine-induced activation ofHIV-1 replication
deserve consideration in formulating guidelines for immunization of HIV-1-infected individu-
als . Given the demonstrated ability of antigenic challenge to activate virus replication in in-
fected individuals, the contribution ofimmune stimulation to T cell depletion and disease pro-
gression in HIV-1-infected individuals are important topics for future study .
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show that T cell activation and proliferation are re-
quired for efficient reverse transcription and nuclear import
of viral preintegration complexes (1-3) . Thereafter, tran-
scription of the integrated provirus is activated by host cell
transcription factors, most notably members of the nuclear
factor KB/rel family, which are induced by T cell activa-
tion (4, 5) . In vivo, most of the HIV-1 viral burden and
expression occur within lymphoid tissues at sites of the
generation of the immune response (6) . Virus is found in
the germinal centers oflymph nodes and in the white pulps
of the spleen (7-9). Recent studies of the dynamics ofviral
replication in vivo have elucidated high levels ofvirus rep-
lication underlying a steady state viremia in AIDS patients
(10-12) . However, little is known about what drives such
substantial HIV-1 replication and determines the steady
state levels of host-virus load.
We were interested in the possibility that antigenic acti-
vation might target specific antigen-responding CD4+ T
cells for HIV-1 infection, virus production, and eventual
destruction. Antigen-specific T cell depletion in HIV-1 in-
fection could be driven by exposure to environmental anti-
gens and might explain the preferential infection and early
loss of memory T cells that have been reported during
HIV-1 infection (13, 14). Demonstration of antigen-spe-
cific T cell depletion in HIV-1 infection would have im-
portant implications for our understanding of AIDS patho-
genesis, as well as for potential strategies to ameliorate
disease progression.
It is generally recommended that HIV-1-infected indi-
viduals be vaccinated against several important pathogens,
including influenza viruses, Streptococcus pneumoniae, Haemo-
philus infuenzae, and hepatitis B (15, 16). In addition, it is
recommended that HIV-1-infected infants be vaccinated
against diphtheria, tetanus, measles, mumps, rubella, polio,
and pertussis. Although the efficacy of these vaccines in im-
munocompetent individuals has been established, the pro-
tective value ofvaccination in the context ofHIV-1 infec-
tion has not been demonstrated (17) . It has been reported
that many HIV-1-infected individuals do not make a sig-
nificant antibody response to vaccine antigens, suggesting
that routine vaccination of HIV-1-seropositive patients
may be of little benefit. In most studies reported to date,
the ability to respond to vaccination correlates with circu-
lating CD4 + T cell levels, and decreases as CD4+ T cell
counts decline and immunodeficiency becomes more se-
vere (17, 18) .
Previous studies, using less sensitive measures than are
currently available, have variously suggested that immune
stimulation may or may not result in increased HIV-1 ex-
pression in vivo (19-21) . We report here the application of
more sensitive virologic methods that demonstrated that
influenza vaccination of HIV-1-infected individuals re-
sulted in transient increases in plasma HIV-1 RNA levels.
Increased viremia was more often seen and of greater mag-
S. 1. Staprans and B. L. Hamilton contributed equally to this work.
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nitude in individuals who displayed T cell proliferative re-
sponses to vaccine antigens at baseline and in those who
mounted a significant serologic response after vaccination.
Kinetic analyses of vaccine-induced changes in viremia
were performed in an effort to elucidate the mechanism
and consequences of antigen-induced activation of HIV-1
replication.
Materials and Methods
Vaccination-induced Activation of HIV-1 Replication
Study Population.
￿
After approval of the study protocol by the
Internal Review Board ofthe Davies Medical Center, 32 subjects
with HIV-1 infection and 10 control subjects confirmed to be
HIV-1 antibody negative by ELISA were recruited from four pri-
vate medical practices and a San Francisco Public Health Depart-
ment Clinic. HIV-1-infected individuals were stratified by CD4+
T lymphocyte levels determined within 30 d of initiation of the
study. Subject characteristics are detailed in Table 1 . Informed
consent was obtained. Blood samples were obtained on the day of
the vaccination and on days 7, 14, 28, and at week 13 after vacci-
nation for virologic and immunologic analyses. All samples were
coded and analyzed by the laboratory in a blinded fashion.
Vaccination, All study participants received a standard dose
(0.5 ml) ofthe 1993-1994 formulation of trivalent influenza vac-
cine (Fluzone split virus preparation; Connaught Laboratories,
Table 1 .
￿
Characteristics of Study Participants
CD4 lymphocyte count
Mean
Median
Range
Previous flu vaccine
57.6
30.0
0-186
343 .8
306.0
260-495
679.8
617.5
529-1020
N/A
N/A
N/A
Yes 8 8 8 3
No 2 1 2 7
Unknown 0 2 1 0
Antiretroviral therapy
during study period
Yes 6 9 4 N/A
No 4 2 7 N/A
AIDS by history of
opportunistic infection
Yes 5 0 0 N/A
No 5 11 11 N/A
CD4 lymphocyte group
0-200 201-500 >500
Control
subjects
Number ofsubjects 10 11 11 10
Men 8 10 10 8
Women 2 1 1 2
Non-Caucasian 1 3 2 1
Age, yr (mean) 39 39 38 37Swiftwater, PA) via intramuscular injection in the deltoid. The
vaccine dose contained 15 jig hemagglutinin (HA)' of A/Texas/
36/91 (HlN1), 15 N,g HA of A/Beijing/32/92 (H3N2), and 15
Vg HA of B/Panama/45/90. The HA of A/Beijing/32/92 re-
placed the HA ofA/Beijing/353/89 (H3N2) that wasincluded in
the 1992-1993 formulation, whereas the A/Texas and B/Panama
antigens were included in both the 1992-1993 and 1993-1994
formulations.
Sample Collection and Preparation.
￿
10-30 ml of acid citrate dex-
tran-anticoagulated blood was obtained from study participants
and processed according to established procedures (22) . For
plasma isolation, blood was centrifuged for 20 min at 400 g, and
then the plasma fraction was removed and recentrifuged for 5
min at 3,000 g to remove cellular debris. The clarified plasma
samples were processedwithin 3 h of initial phlebotomy. PBMC
were isolated by Ficoll-Paque (Pharmacia Biotech, Inc., Piscat-
away, NJ) density gradient centrifugation as described (22). Puri-
fied PBMC were viably cryopreserved in liquid nitrogen (22) .
Quantitation ofPlasma and Cellular HIV-1 RNA Levels.
￿
Levels
ofvirion-associated HIV-1 RNAwere measured usingthe HIV-1
branched DNA (bDNA) signal amplification method (Quantiplex
HIV-1 RNA assay; Chiron Corp., Emeryville, CA) as described
(23). Plasma samples yielding values of HIV-1 RNA levels below
the bDNA cutoff (<10,000 copies HIV-1 RNA/ml of plasma)
were reassayed by the HIV-1 quantitative competitive (QC) PCR
method with the following modifications (24, 25): (a) HIV-1
RNA was isolated from virions pelleted from 1-3 ml of plasma
using the Trizol (GIBCO BRL, Gaithersburg, MD) RNA ex-
traction method. (b) For very low copy number samples, the
competing RNA template series consisted of 0, 25, 50, 100, 500,
1,000, and 5,000 copies per reaction. (c) The thermal cycling
conditions used were 94°C for 3 min (1 cycle); 93°C for 30 s,
55°Cfor 30 s, 72°C for 1 min (45 cycles); 72°C for 10 min (1 cy-
cle) ; 4°C hold. (d) PCR products were radioactively labeled by
the addition of [32P]dCTP to the PCRreaction mix, followed by
resolution of the PCR products by electrophoresis on 6% acryla-
mide gels and quantitation by phosphorimage analysis usingabio-
imager (FujixBas 1000 Bio-Imaging Analyzer; Fujix, Inc., Stamford,
CT). With these modifications, the QC-PCR method has a sensi-
tivity of ^100 copies of HIV-1 RNA/ml ofplasma. Competition
equivalence points were determined by interpolation on plots of
the logarithm of the calculated ratio of signal for the wild-type
target sequence-derived product (corrected for molar ratio) versus
the logarithm of the copy number of added competitive template.
For quantitation of HIV-1 mRNA present within PBMC, total
cellular RNAwas prepared from Ficoll-Hypaque-purified PBMC
by the Trizol RNA extraction method. RNA, prepared from
-105 PBMC, was reverse transcribed into cDNA and subjected
to QC-PCR as described above.
Immunophenotyping.
￿
PBMC were obtained from acid citrate-
anticoagulated blood samples by Ficoll-Hypaque separation. Ali-
quots o£cells were stained with optimal concentrations ofapanel
of r Abs, as described (26) . A minimum of 10,000 stained cells
was analyzed on a FACScan® flow cytometer (Becton Dickinson
& Co., Mountain View, CA) using two-color analysis and the
Lysis II analysis software. Markers analyzed included CD3, CD4,
CD8, CD45RA, CD45RO, and HLA-DR (mAb) reagents ob-
tained from Becton Dickinson & Co.) to define various subpopu-
lations ofthe CD4+ T cells (26) . The results were expressed as a
percentage of the lymphocytes stained with each mAb. Absolute
'Abbreviations used in this paper: bDNA,branched DNA; HA,hemaggluti-
nin; HBV, hepatitis B virus; QC, quantitative competitive.
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numbers of each population were calculated at the initiation of
the study. CD45RA identifies a population of immature CD4+ T
cells; CD45RO identifies a population of mature CD4+ T cells;
and HLA-DR identifies a population ofactivated CD4+ T cells.
Cell-mediated Immune Responses.
￿
Cell-mediated immune re-
sponses to influenza and control antigens were assessed by the in
vitro proliferation of PBMC to specific antigenic stimulation us-
ing a standard assay (26) . Briefly, 105 cryopreserved PBMC were
cultured in U-bottom microtiter plates in RPMI 1640 medium
supplemented with 25 mM Hepes, 10%human AB' serum (Sigma
Chemical Co., St. Louis, MO), 1% t-glutamine, 1% penicillin,
and 1% streptomycin. A concentration ofeach antigenpreviously
shown to yield optimal proliferative responses from human
PBMC was added to appropriate wells, and the plates were incu-
bated for 6 d at 37oC in a humidifed atmosphere containing 5%
CO2. For the last 18 h of incubation, 1 RCi [3H]TdRwas added
to each culture. The cells were harvested onto glass fiber filters
using a 96-well harvester and prepared for liquid scintillation
counting in a counter (BetaPlate; Wallac, Gaithersburg, MD).
Antigens used included the trivalentvaccine antigen (Connaught
Laboratories) diluted 1:50, 1 :100, and 1:500; tetanus toxoid
(Connaught Laboratories) at a final concentration of 4 Lf/ml; and
Candida antigen (Greer Labs, Lenoir, NC) at afinaldilution of 10
N.g/ml. The number of cells added to each well was adjusted to
partially normalize the number ofCD4+ T cellsin each well. For
subjects with CD4 counts >500, 105 cells were added to each
well. For subjects with CD4 counts between 200 and 500, 2 X
105 cells were added, and 4 X 105 cells were added for subjects
with CD4 counts <200. The mean counts per minute from trip-
licate cultures were calculated. Results are described as a stimula-
tion indexequal to mean counts perminute ofantigen-stimulated
cultures/mean counts per minute of media control cultures. A
stimulation index--2.5 was considered a positive proliferative re-
sponse. This assay measures the proliferative response of mature
CD45RO+CD4+ T memory cells. A positive response requires
the previous in vivo stimulation of the T cell compartment with
the specific antigen.
Antibody Response to Influenza Antigens.
￿
Plasma antibodies to in-
fluenza antigens were measured in a standard hemagglutinin inhi-
bition assay using 0.5% chicken red blood cells as described (27).
The assay was performed using monovalent influenza antigens
from the 1993-1994formulation kindly supplied by Wyeth-Ayerst
Laboratories (Marietta, PA). Nonspecific inhibitors were removed
from citrated plasma by treatment with Kaolin (28). The initial
dilution of plasma was 1:10 with subsequent twofold dilutions.
Titers were expressed as the reciprocal dilution giving complete
inhibition of hemagglutinin. A significant increase in antibody
titers was defined by a fourfold or greater increase in plasma anti-
body titer in samples obtained 4 wk after immunization.
Statistical Analyses.
￿
Proportional data were compared using
Fisher's exact test. Correlations were determined using Spear-
man's rank correlation test. For analysis ofthe kinetics of change
in plasma HIV-1 RNA levels, values of plasma viral RNA copy
number were transformed to a natural logscale to normalize vari-
ance and to facilitate the use of linear analysis methods. The rate
of viral population growth was estimated as the slope of the line
drawn between the prevaccination viral copy number and the
peak viral copy number after vaccination. The rate ofviral popu-
lation decline was estimated as the slope of the line drawn be-
tween the peak viral copy number and the first time point after
peak viremia. These rates provide minimum estimates of growth
and decline of the viralpopulation because the real peak viremia
may have been higher, but could not have been lower, than themeasured peak. Doubling time and half-life were calculated by
dividing the natural log of 2 by the rates of viral population
growth and decline, respectively. Linear regression was used to
analyze associations between CD4+ T cell counts and the rates of
viral population growth and decline. Analysis was performed us-
ing Statistical Analysis Software (SAS Institute, Inc., Cary, NC.
Results
StudyPopulation and Design.
￿
32 adult subjects with HIV-1
infection, equally distributed with respect to CD4+ T cell
counts (0-1,020), and 10 seronegative control subjects were
recruited from private and public medical clinics (see Table
1 and Materials and Methods) . For data analysis, HIV-1-
infected individuals were stratified by CD4+ T lymphocyte
counts into three groups of 0-200, 201-500, and >500
CD4+ T lymphocytes/Vl. All study subjects received a
standard dose ofthe 1993-1994 formulation ofthe trivalent
influenza vaccine via intramuscular injection, and blood
samples were obtained before vaccination and on days 7,
14, 28, and at week 13 after vaccination for virologic and
immunologic analyses. The mean age of the study partici-
pants was similar between the different groups, but HIV-1-
infected participants were more likely to have been previously
vaccinated against influenza. The majority ofHIV-1-infected
participants were receiving antiretroviral therapy (with the
nucleoside analogues zidovudine, zalcitabine, didanosine,
or stavudine monotherapy or various combinations thereof)
before and during the study period. None of the study par-
ticipants had evidence of active opportunistic infections at
the time of study entry. There were no adverse clinical re-
actions to the influenza vaccine and there were no reports
of an influenza-like illness.
Immunophenotyping.
￿
To determine whether there were
any significant changes in the representation oflymphocyte
subsets in the peripheral circulation after vaccination, we
measured the cell surface expression of a number of lym-
phocyte markers. Considerable variation in the percentages
of CD3+ (TCR+) T lymphocytes (range 39-90%), CD4+
T lymphocytes (range 1-48%), CD8+ T lymphocytes
(range 22-67%), CD4+CD45RA+ ("naive") T lympho-
cytes (range 12-97%), CD4+CD45R0+ ("memory") lym-
phocytes (range 21-82%), CD4+HLA-DR' (activated) T
lymphocytes (range 2-31%), and CD4/CD8 ratios (range
0.02-2.18) wer present in the peripheral blood of HIV-1+
subjects before vaccination. With the exception of the
HLA-DR+ population o£ CD4+ T cells, the percentages of
these T lymphocyte populations remained essentially con-
stant for each individual HIV-l+ subject studied during the
4-wk observation period after vaccination. In the HIV-1+
individuals, the median percentage of HLA-DR+ T cells
fell from 11 to 1% by 4 wk after vaccination (P <0.0001).
A decrease in the percentage of activated (HLA-DR+)
CD4+ T lymphocytes was observed in 10 of 10 subjects
who had elevated percentages at the beginning of the
study. In contrast, the median percentage of HLA-DR'
CD4+ T cells in the seronegative controls remained con-
stant at 1%. It is not possible to determine whether the ob-
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served decrease in HLA-DR' cells in HIV-infected indi-
viduals is due to loss or redistribution ofthe cells, but these
changes are unlikely to be explained on the basis of an ef-
fect on influenza-specific T cells alone, which constitute
only a tiny fraction ofthe circulating T cell population.
T Cell Proliferation. In vitro proliferation assays were
performed to assess the integrity of T cell responses to the
influenza antigens (14) . In vitro proliferation of T cells is a
measure of antigen-specific CD4+CD45R0+ T memory
cells. Consistent with previous reports, the proportion of
subjects responding to the influenza vaccine antigens and
the magnitude of the proliferative response both increased
with increasing CD4 counts (Fig. 1). At least some individ-
uals in each study group responded to the influenza vaccine
antigens in vitro: two of seven subjects (29%) with CD4
counts <200; 7 of 11 subjects (64%) with CD4 counts
200-500; and nine of nine subjects (100%) with CD4
counts >500. 4 wk after vaccination, diminished T cell
proliferative responses were seen in most people, including
seronegative control subjects, suggesting that the influenza-
responsive cells are not present in the peripheral circulation
at this time. This unexpected finding precluded us from de-
termining whether vaccination may have actually resulted
in a loss rather than an expansion of influenza-specific
CD4+ T cells in HIV-1-infected individuals.
Antibody Responses to Vaccine Antigens.
￿
Antibody responses,
an essential functional measure of the integrity o£ the
CD4+ T cell-dependent immune response, were measured
before and after vaccination. Poor antibody response to
A/Texas/36/91 and B/Panama/45/90 were observed in all
of the study groups, including the uninfected control sub-
jects (Table 2). The A/Beijing/32/92 antigen was more
immunogenic in all of the study groups. The proportion of
subjects that made a significant increase in antibodies (de-
fined as a fourfold or greater increase in titer) increased in
proportion to the CD4 count. However, only the study
group with CD4 counts <200 demonstrated a significantly
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Figure 1 .
￿
T cell proliferative response to influenza vaccine antigens, ac-
cording to CD4 count. The proportion of subjects responding and the
magnitude ofthe in vitro proliferative response ofmature CD4+ T mem-
ory cells increases the CD4 count in HIV-seropositive subjects.Table 2.
￿
Antibody Response to the 1993-1994 Influenza Vaccine in HIV-seropositive Subjects According to CD4 T Lymphocyte Count
(P <0.05) lower proportion of responders (20%) compared
with the control groups (80% responders) .
All of the study subjects had detectable antibody to both
the A/Texas/36/91 and B/Panama/45/90 antigens before
vaccination with the 1993-1994 vaccine. Prevaccination
antibodies to the A/Beijing/32/92 antigen were present in
20% of the control and 38% of the seropositive subjects.
These data most likely reflect the fact that the seropositive
subjects had received routine influenza vaccination over
the past several years, whereas the subjects in the control
group were less likely to have been previously vaccinated
against influenza.
Changes in Plasma Viremia.
￿
Levels of virion-associated
HIV-1 RNA in the plasma are a good indicator of the level
of ongoing virus replication in the body (10-12) . We used
the bDNA and QC-PCR methods to measure HIV-1
RNA in the plasma at weeks 0 (preimmunization), 1, 2, 4,
and 13 relative to immunization (23-25). These two assays
generate measures with a high degree of correlation (29
and our unpublished data). Taking into account the coeffi-
cient of variation within individual bDNA and QC-PCR
assays, as well as the small biological variation in plasma
HIV-1 RNA levels in clinically stable HIV-1-infected in-
dividuals, we considered a threefold change in the level of
plasma HIV-1 RNA to be significant (23, 30). By this cri-
terion, the majority (83%) ofvaccinated individuals experi-
1731
￿
Staprans et al.
*Data presented as geometric range of antibody titers in hemagglutination inhibition units in samples obtained before and again 4 wk after immuni-
zation.
$Percentage ofsubjects with detectable antibody in the preimmunization sample.
§Percentage ofsubjects with a four fold or greater increase in antibody titers after immunization.
IIP <0.05 compared with control subjects by Fisher's exact test.
enced a significant increase in plasma HIV-1 RNA levels
within 1-2 wk immunization and returned to their prevac-
cination levels within 4 wk after immunization (Table 3;
P = 0.0009). The mean fold increase in HIV-1 RNA copy
number was substantially greater in those individuals with
higher CD4+ T cell counts (Fig. 2) . At baseline, before im-
munization, the individual plasma HIV-1 RNA copy num-
ber measures covered a wide range (50-402,500 copies/
ml) . After immunization, the peak titers observed had a sig-
nificantly more narrow distribution (range 5,800-1,600,000
copies/ml; Fig. 3; P = 0.0009) . Among all HIV-1-infected
participants, peak plasma HIV-1 RNA levels seen after vac-
cination ranged from 1- to 369-fold above baseline values
(median 7.3) . For individuals with <200 CD4+ T cells/~tl,
Table 3.
￿
Percentage ofSubjects uath Greater than Threefold
Increase in Plasma Viremia
Antigen Group n
Preimmunization
Mean Range
titers*
Positives Mean
Postimmunization
Range
titers
Responders§
A/Texas/36/91 Control subjects 10 34.8 20-80 100 60.6 40-320 30
All HIV+ 32 48.6 10-160 100 57.8 20-640 6
CD4 <200 10 49.2 40-80 100 45.9 40-80 0
CD4 200-500 12 50.4 20-320 100 53.4 40-80 0
CD4 >500 10 45.9 10-160 100 80.0 20-640 20
A/Beijing/32/92 Control subjects 10 1 .7 0-20 20 30.3 10-80 80
All HIV+ 32 2.8 0-40 38 15.7 0-640 41
CD4 <200 10 3.1 0-40 40 11 .8 0-80 2011
CD4 200-500 12 3.3 0-20 42 15.0 0-160 42
CD4 >500 10 2.1 0-20 30 22.0 0-640 60
B/Panama/45/90 Control subjects 10 45.9 20-160 100 105.6 40-320 30
All HIV+ 32 68.7 20-320 100 110.7 40-1280 9
CD4 <200 10 76.6 40-320 100 85.7 40-320 0
CD4 200-500 12 59.9 20-160 100 95.1 40-320 8
CD4 >500 10 74.6 40-320 100 171 .5 80-1280 20
Wk after
immunization CD4 <200 CD4 200-500 CD4 >500
1 30 36 60
2 78 67 90
4 50 17 40
13 33 27 0W
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Figure 2.
￿
Tempo of plasma viremia by CD4 group. The mean fold in-
crease in plasma HIV-1 RNA copy number at weeks 1, 2, 4, and 13 after
influenza vaccination is shown. Bars indicate SEM.
peak post-vaccination plasma HIV-1 RNA levels ranged
from 1- to 52-fold above baseline values (median 4.0). Par-
ticipants with 200-500 CD4+ T cells/~Ll showed peak
postvaccination plasma HIV-1 RNA levels ranging from
1- to 89-fold above their baseline determinations (median
5.1) . For those with >500 CD4+ T cells/~Ll, peak postvac-
cination elevations in plasma HIV-1 RNA levels ranged
from 1 .4- to 369-fold above baseline measurements (me-
dian 33) . Patients on antiretroviral therapy were not no-
ticeably different from those not in therapy with regard to
increases in plasma viremia. In a few patients, plasma vire-
mia did not return to baseline or showed a second increase
during the study. None of these study participants were
given a second vaccination during the study period, but
these few subjects did have evidence o£ an intercurrent in-
fection, such as the development of CMV retinitis or Pneu-
mocystis carinii pneumonia, which may have caused the sec-
ond wave of viremia.
To evaluate the impact of vaccination on rates o£ HIV-1
replication and clearance, we calculated the doubling times
and half-lives of plasma virus from the rates of change of
plasma HIV-1 RNA levels after vaccination. Rates of viral
Pre-
￿
Peak
vaccination
Figure 3 .
￿
Baseline viremia before vaccination and the peak viremia oc-
curring 7-21 d after vaccination. Each line represents one patient. Bars
represent the median ± the mean of the absolute differences from the
median, which is a measure ofvariance. Median viremia was lower before
vaccination (Wilcoxin two sample test, P <0.0001) and was more vari-
able (modified Levene median test, P = 0.0009 [54]). Statistical tests were
performed after logarithmic transformation.
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population growth were correlated with rates of viral pop-
ulation decline after peak viremia (Fig. 4 A; P = 0 .0002).
Subjects with higher baseline CD4+ T lymphocyte counts
had higher rates ofviral growth after vaccination (Fig. 4 B;
P = 0.0007) and higher rates of viral decline after peak
viremia (Fig. 4 C; P = 0.01) . The fold increase in viremia
was higher in patients with higher CD4+ T cell counts be-
fore immunization (Fig. 4 D; P = 0.05) .
We also quantitated the levels of PBMC-associated
HIV-1 RNA by QC-PCR at time points before and after
immunization. There were no significant changes in PBMC
HIV-1 RNA levels detected (data not shown), even in in-
dividuals with large increases in plasma viremia. The failure
to detect elevations of HIV-1 RNA after vaccination sug-
gests that the increase in plasma virus was originating from
virus produced at other sites in the body, most likely the
peripheral lymphoid organs, and that virus-producing cells
do not survive to recirculate through the peripheral blood-
stream.
Association between Immune Responses and Changes in Plasma
Viremia. To evaluate whether there was any significant
correlation between an immune response to influenza anti-
gens and increases in plasma viremia, we performed statisti-
cal analysis of the data. A large increase (>10X) in plasma
HIV RNA was observed in subjects who made an immune
response to the vaccine antigens (Fig. 5). The correlation
between the increase in plasma viremia and immune re-
sponse was significant for both the presence ofa T cell pro-
liferative response to the vaccine antigens (P = 0.01) or the
presence of a significant (fourfold or greater) increase in an-
tibody titer (P <0.001) to one or more ofthe vaccine anti-
gens by Spearman rank order analysis. It should be noted
that several individuals with low CD4+ T cell counts dem-
onstrated both a measureable influenza-specific immune re-
sponse and large increases in plasma viremia. Thus, it ap-
pears that vaccine stimulation of influenza-specific T cells
in vivo leads to activation of HIV-1 replication.
Discussion
It is plausible that T cell depletion in HIV-1 involves
specific antigen-driven loss of T cells as opposed to a more
random process of T cell depletion. Pathogens that plague
HIV-1-infected individuals early in the course of infection
include those that are either prevalent in the environment
(Candida spp.), or cause persistent infections (Mycobacterium
tuberculosis, herpes simplex virus, varicella zoster virus) (31).
The nature of the opportunistic infections seen in HIV-1-
infected individuals and the timing with which these infec-
tions occur in the course of HIV-1 disease may be the re-
sult of the preferential depletion ofCD4+ T cells that respond
to commonly encountered antigens. Exogenous antigens
(such as those that are prevalent in the environment) or en-
dogenous antigens (such as those produced by latent infec-
tious pathogens) might result in the frequent activation of
host antigen-specific CD4+ T cells, thus increasing their
susceptibility to HIV-1 infection and destruction. With time,
the gradual attrition ofthe CD4+ T cell-protective responseE
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Relationship between an immune response to the influenza
vaccine antigens and an increase in plasma HIV RNA copy. Greater in-
creases in plasma HIV RNA copies were observed in subjects who made
an immune response to the influenza vaccine antigens (A) compared with
those who did not ("), either as a T cell proliferative response (left) or as a
fourfold or greater antibody response (right). P values were calculated by
Mann-Whitney rank test.
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(A) The rate ofplasma viral
population growth after influenza vacci-
nation and the rate of viral population
decline after peak viremia. (B) The rate
of plasma viral population growth and
prevaccination circulating CD4 lym-
phocyte count. (C) The rate of plasma
viral population decline and prevaccina-
tion circulating CD4 lymphocyte count.
(D) The fold increase in viral load and
prevaccination circulating CD4 lympho-
cyte count. Each point represents one pa-
tient. Rates were calculated as described
in the Materials and Methods. The solid
lines represent best fits by linear regres-
sion. Associations were significant in all
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may predispose the host to infection with specific opportu-
nistic pathogens. Although experimental evidence for this
hypothesis has not been pursued previously, certain clinical
observations are consistent with its predictions. HIV-1 in-
fection around the time of hepatitis B vaccination increases
the risk of chronic hepatitis B virus (HBV) carriage, sug-
gesting that HIV-1 may preferentially target HBV-reactive
T cells for infection and depletion (32) . In the setting of
HIV-1 infection, it is reported that acyclovir therapy in
individuals with a prior history of herpesvirus infection,
and isoniazid therapy in tuberculin skin test-positive indi-
viduals, confer survival advantage and delay disease progres-
sion, respectively (33, 34). These observations suggest that
reducing the chronic antigenic stimulation caused by these
pathogens is beneficial. However, further study is needed
to determine whether opportunistic infection-induced vi-
rus activation leads to a faster rate of HIV-1 disease pro-
gression. If antigen-driven constriction in the repertoire of
T cell antigen recognition were demonstrated, this would
argue for early antiviral intervention in HIV-1 disease to
preserve an intact and diverse repertoire. If loss of the di-
versity of T cell antigen recognition was irreversible, then
T cell repletion by antiviral therapy or lymphokines such as
IL-2 in intermediate- or late-stage disease might be of lim-
ited use (11, 12, 35).
To better understand the effects of antigen activation in
HIV-1 infection, we performed an observational study of
HIV-1-infected individuals receiving influenza vaccina-
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0- 0-tion. Large increases in plasma HIV-1 RNA were observed
in the majority of patients given the influenza vaccine.
Plasma viremia peaked 1-2 wk after immunization and re-
turned to baseline levels in the majority ofpatients within 4
wk. Virus load increases manifest a time course that paral-
lels the kinetics of the generation of the immune response
to the influenza vaccine (36), suggesting that increased
plasma viremia occurs as a consequence of vaccine-induced
activation o£influenza-responsive CD4+ T cells (21, 36-39).
Furthermore, increases in plasma viremia were higher in
those individuals who responded immunologically to the
vaccine antigens, compared with those who responded
poorly. This result and other recent studies point to virus
production arising from continued new rounds of infection
ofsusceptible target cells (11, 12).
The magnitude of increases in plasma HIV-1 levels was
surprisingly large, suggesting that they were unlikely to be
due to HIV-1 replication in influenza-responsive T cells
alone . Rather, the antigen-responsive cells might be neces-
sary to initiate an inunune response that is then further am-
plified by cytokine activation of additional non-antigen-
specific cells (40-42). Such amplification of the immune
response may increase indirectly the pool of susceptible tar-
get cells. Recent evidence suggests that immune activation
may indeed increase the population of cells susceptible to
HIV-1 infection (Fauci, A., HIV Pathogenesis Meeting,
Keystone, CO 1995) . Further, we have recently found that
vaccination of rhesus macaques around the time of experi-
mental simian immunodeficiency virus infection results in a
significant accleration of the rate ofsubsequent disease pro-
gression, perhaps the result of creation of a larger pool of
cells susceptible to virus infection or compromise of the ef-
ficacy of the host antiviral immune responses (Staprans, S.,
and M. B. Feinberg, manuscript in preparation) .
Recent kinetic studies using potent antiviral agents to in-
hibit HIV-1 replication demonstrate that the measured lev-
els of plasma HIV-1 RNA reflect a steady state that is pri-
marily determined by the rate ofongoing virus production,
rather than rates of clearance, which were relatively uni-
form in the patients studied (11, 12) . Analysis of the kinet-
ics of plasma viremia after vaccination revealed that the in-
crease in viremia was proportional to the prevaccination
CD4+ T cell count. Patients with low CD4+ T cell counts
tended to have slower rates of viral load increases, lower
rates of viral decline, and lower fold increases in viremia.
Such patterns ofviremia might arise from an initially slower
but then more prolonged phase ofimmune activation. Ad-
ditionally, or alternatively, less efficient immune contain-
ment of virus-producing cells might be occurring in these
patients. Viremia is both induced and suppressed more
quickly in individuals with high CD4+ T cell counts. Opti-
mal virus suppression after peak viremia in the healthiest,
highest vaccine responder was manifested by a measured
virus half-life of 1 .6 d. This calculated half-life of plasma vi-
rus is similar to the viral clearance rates described in recent
studies using potent antiviral drugs (11, 12), suggesting that
the antiviral immune response may, in the best of circum-
stances, contain HIV-1 replication as effectively as the most
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active antiviral drugs available. More potent virus suppres-
sion in individuals with higher CD4+ T cell counts may re-
flect more active immune destruction o£ infected T cells,
perhaps by cytotoxic T lymphocytes, as opposed to a non-
immune-mediated cytolysis of HIV-1-infected cells. Per-
haps the measured rate of containment of HIV-1 produc-
tion after vaccination could be used as a means of assessing
the integrity of the antiviral immune response in vivo.
Chronic basal antigenic activation of the immune system
may contribute to the observed steady-state viral load in
HIV-1-infected patients. Alternatively, the steady-state vi-
rus load may be due to a non-antigen-driven mechanism
involving continued proliferation and replenishment oflost
CD4+ T lymphocytes (11, 12). It is interesting that, after
substantial increases in plasma viremia, almost all of the
subjects returned to their previous baseline values ofplasma
viremia. This suggests that the steady state may result from
(a) the number of new cycles of viral infection, which is
perhaps determined by the host's immune activation status;
and (b) the efficiency ofthe host antiviral immune response.
The state of activation of the host immune system is ex-
pected to determine the number of target cells available for
HIV-1 infection, whereas the vigor of the host antiviral im-
mune response is expected to determine the number of
HIV-1-producing cells present in an infected individual. It
is notable that, although a number of the individuals stud-
ied displayed low steady state levels of plasma viremia, pre-
sumably the result of effective immune containment of
HIV-1 replication, they were unable to prevent the surge
in virus replication seen afterinfluenza vaccination. The dem-
onstration ofmore rapid rates ofincrease in viremia in indi-
viduals with higher CD4+ T cell counts and the more re-
stricted range o£ plasma HIV-1 RNA levels seen among
study participants at peak viremia after vaccination are con-
sistent with the importance that the size of the pool of sus-
ceptible target cells plays in determining the level of ongo-
ing HIV-1 replication in infected individuals.
Antiretroviral therapy initiated at various times before
influenza vaccination did not prevent increases in plasma
viremia. We cannot distinguish whether this is due to the
relative ineffectiveness of the nucleoside analogues available
at the time this study was conducted or the presence of
drug-resistant viruses in treated patients before vaccination.
Treatment with more potent antiviral drugs (11, 12) might
be more effective at blunting the activation ofHIV-1 repli-
cation after vaccination. In addition, future studies of the
use ofthese agents in the setting o£vaccination should per-
mit delineation of the relative contributions to increased
viremia of the activation of latently infected T cells or the
increased availability of susceptible target cells after anti-
genic stimulation. Further, should antiviral drugs be identi-
fied that effectively limit antigen-induced increases in HIV-1
viremia, they might improve the immune responses to vac-
cination in treated individuals and provide an approach to
limit the damage that may potentially result from vaccine-
or infection-induced activation of virus replication.
Although we have no evidence to suggest that influenza
vaccination was ofany clinical detriment to HIV-1-infectedindividuals, it is reasonable to be concerned about the sub-
stantial, albeit transient, increase in HIV-1 load seen after
immunization. Potentially, increased plasma viremia may
induce the destruction of either a specific antigen-reactive
component of the T cell repertoire, or a more general non-
antigen-specific component, or both. However given the
significant activation ofvirus production that follows a dis-
crete vaccine-induced antigenic exposure, it is likely that
the immune activation associated with an actual opportu-
nistic infection may cause even more dramatic stimulation
ofvirus production. These issues must be considered in de-
termining the advisability of particular vaccines. Our addi-
tional anecdotal experience suggests that acute M. tuberculo-
sis and P. carinii infections can cause increased viral load
(Staprans, S ., and M. B. Feinberg, unpublished observa-
tions) . Indeed, intercurrent infections occurred in a few of
the influenza-vaccinated patients whose plasma viremia lev-
els either did not return to baseline values or who mani-
fested a second, later peak in plasma viremia.
The efficacy of influenza immunization in the HIV-1-
seropositive population remains to be deternined (43, 44).
The current recommendations concerning influenza vacci-
nation of HIV-1-infected individuals stem from analogies
made to individuals with other types ofimmunodeficiency.
However, the close link between immune activation and
HIV-1 replication suggests that this reasoning may be
flawed. Our results, as well as those ofothers, show that the
influenza vaccine is poorly immunogenic in the HIV-1+
population, with the lack of immunogenicity being linked
to the degree of immune deficiency (18, 45-47). Influenza
is not felt to be an important pathogen in HIV-1+ individ-
uals, although this population is at increased risk for bacte-
rial infections (Staphylococcus aureus, S. pneumoniae, and H.
influenzae) associated with postinfluenza secondary pneu-
monias (48). Furthermore, an alternative (albeit cumber-
some) approach involving prophylaxis with amantidine is
available for influenza-exposed people should future studies
demonstrate a detrimental impact of influenza vaccination
of HIV-1-infected individuals.
Evaluation of the role of vaccination as a prevention
strategy for other pathogens such as S. pneumoniae, H. influen-
zae, or HBV that are important causes ofdisease in HIV-1-
infected individuals may be quite different (49-51) . The
multivalent pneumococcal capsular polysaccharide vaccine
(Pneumovax) appears to elicit a better immune response
than does the influenza vaccine (45, 52) . However, like in-
fluenza vaccination, pneumococcal vaccination also results
in transiently increased levels of HIV-1 replication in many
HIV-1-infected individuals (Stevenson, M., personal com-
munication). H. influenza B vaccine also elicits a more po-
tent immune response in HIV-1-infected individuals, al-
though immunization early in disease may be required to
obtain levels of antibody response that correlate with pro-
tection from infection (53). Prevention of HBV infection
through vaccination is clearly important in people at risk
for HIV-1 infection. In light of our results and those of
others (Stevenson, M., personal communication), it will be
important to carefully weigh the risks and benefits of indi-
vidual vaccines in the context of both pediatric and adult
HIV-1 infection.
It is hoped that the recently developed methods to mon-
itor HIV-1 RNA levels in the plasma, including the tech-
niques used in this study, will provide valuable tools to as-
sess the risk ofdisease progression and the efficacy ofantiviral
drugs in infected individuals (23, 24, 29) . However, little
information is available concerning the factors that influ-
ence the biological variation of these new assays. The ob-
served changes in plasma viremia aftervaccination or infec-
tion by pathogens are important to consider in determining
the clinical utility of HIV-1 RNA assays, as such perturba-
tions may significantly influence the interpretation of viral
load measures.
Further studies will be required to elucidate the possible
pathogenic consequences of immune stimulation in HIV-1
infection. It is important to determine whether environ-
mental or vaccine-associated antigenic stimulation results in
antigen-specific constriction of the T cell repertoire and
progression of HIV-1 disease.
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